BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38050454)

  • 1. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
    Chandekar KR; Satapathy S; Bal C
    Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
    Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
    Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Postoperative Adjuvant Radioactive Iodine Ablation Therapy Always Necessary for Intermediate-Risk Papillary Thyroid Cancer Patients With Central Neck Metastasis?
    Han K; Noh HM; Jeong HM; Lim YC
    Ann Surg Oncol; 2021 Nov; 28(12):7533-7544. PubMed ID: 34043093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
    Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
    Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
    Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
    Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Radioactive Iodine Therapy on Cancer-Specific Survival of Papillary Thyroid Cancer Tall Cell Variant.
    Dai P; Zhao W; Zheng X; Luo H; Wang X
    J Clin Endocrinol Metab; 2024 Feb; 109(3):e1260-e1266. PubMed ID: 37804527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
    Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
    Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma.
    Sun W; Di L; Chen L; Li D; Wu Y; Xiang J; Zhou S; Sun T
    BMC Surg; 2022 Nov; 22(1):374. PubMed ID: 36324095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence.
    Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J
    Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy.
    Papachristos A; Do K; Tsang VH; Sywak M; Gill AJ; Sidhu S; Clifton-Bligh RJ; Glover A; Gild ML
    Thyroid; 2022 Sep; 32(9):1086-1093. PubMed ID: 35703333
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical impact of radioactive iodine dose selection based on the number of metastatic lymph nodes in patients with papillary thyroid carcinoma: A multicenter retrospective cohort study.
    Kwon SY; Kim MH; Kong E; Chong A; Yoo SW; Jeon S; Park SA; Kim DW; Kang SH; Choi JE; Ha JM; Jeong SY; Lee SW
    Clin Endocrinol (Oxf); 2021 Dec; 95(6):901-908. PubMed ID: 34185324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Patients with an Intermediate-Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma.
    Horiuchi K; Fujimoto M; Hidenori K; Yoshida Y; Noguchi E; Omi Y; Okamoto T
    World J Surg; 2023 Oct; 47(10):2464-2473. PubMed ID: 37266697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
    Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
    ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodine versus no radioiodine outcomes in low-risk differentiated thyroid cancers: A propensity-score matched analysis.
    Satapathy S; Tupalli A; Chandekar KR; Ballal S; Bal C
    Clin Endocrinol (Oxf); 2023 Nov; 99(5):483-491. PubMed ID: 37491776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
    Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
    Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.
    Grigsby PW; Reddy RM; Moley JF; Hall BL
    Surgery; 2006 Dec; 140(6):1043-7; discussion 1047-9. PubMed ID: 17188155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.